{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:55:13Z","timestamp":1791060913045,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jiph.2026.103356","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T14:54:54Z","timestamp":1788706494000},"page":"103356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy, immunogenicity and safety of RTS,S\/AS01, R21\/Matrix-M and candidate malaria vaccines in children: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-3538","authenticated-orcid":false,"given":"Katsiaryna","family":"Bashlakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7193-1900","authenticated-orcid":false,"given":"Marianna","family":"Zarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Villari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"De Vito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-5130","authenticated-orcid":false,"given":"Annalisa","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103356_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1473-3099(02)00344-4","article-title":"The immune response to Plasmodium falciparum malaria","volume":"2","author":"Malaguarnera","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib2","unstructured":"World malaria report 2025: addressing the threat of antimalarial drug resistance. 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240117822 (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib3","unstructured":"Global technical strategy for malaria 2016\u20132030. 2015. https:\/\/iris.who.int\/handle\/10665\/176712 (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib4","series-title":"Highlights from the meeting of the Strategic Advisory Group of Experts (SAGE) on immunization, 22-25 September 2025","first-page":"22","author":"WHO","year":"2025"},{"key":"10.1016\/j.jiph.2026.103356_bib5","article-title":"Economic burden of malaria on developing countries: a mini review","volume":"30","author":"Mezieobi","year":"2025","journal-title":"Parasite Epidemiol Control"},{"key":"10.1016\/j.jiph.2026.103356_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1475-2875-12-307","article-title":"The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya","volume":"12","author":"Sicuri","year":"2013","journal-title":"Malar J"},{"issue":"9","key":"10.1016\/j.jiph.2026.103356_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-3024.2009.01143.x","article-title":"The development of the RTS, S malaria vaccine candidate: challenges and lessons","volume":"31","author":"Ballou","year":"2009","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.jiph.2026.103356_bib8","first-page":"21","article-title":"Systematic review of safety of RTS, S with AS01 and AS02 adjuvant systems using data from randomized controlled trials in infants, children, and adults","author":"Yihunie","year":"2023","journal-title":"Clin Pharm Adv Appl"},{"key":"10.1016\/j.jiph.2026.103356_bib9","unstructured":"MEDIA ADVISORY: President Mahama to Launch \u2018The Accra Reset\u2019 at UNGA 2025. - The Presidency, Republic of Ghana. https:\/\/presidency.gov.gh\/media-advisory-president-mahama-to-launch-the-accra-reset-at-unga-2025\/ (accessed Dec 15, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib10","unstructured":"African health leaders and global partners unite to confront the rising threat of antimalarial drug resistance [news release]. 2025; published online May 20. https:\/\/www.who.int\/news\/item\/20-05-2025-african-health-leaders-and-global-partners-unite-to-confrontrising- threat-of-antimalarial-drug-resistance (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib11","unstructured":"FG Convenes High-Level Dialogue on Power in Health Sector, 09 -10 September 2025 - Federal Ministry of Health and Social welfare. https:\/\/health.gov.ng\/fg-convenes-high-level-dialogue-on-power-in-health-sector-09-10-september-2025\/ (accessed Dec 15, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib12","unstructured":"Weekly epidemiological record Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire. 10 MAY 2024, 99th YEAR \/ 10 MAI 2024, 99e ANN\u00c9E No 19, 2024, 99, 225\u2013248. 2024. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/8b85664c-33a0-4366-bde7-5ba0c0ccea72\/content (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2026.103222","article-title":"Efficacy and immunogenicity of RTS, S\/AS01 and R21\/Matrix-M malaria vaccines:-systematic review and meta-analysis","author":"Asjad","year":"2026","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jiph.2026.103356_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2026.103356_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","article-title":"Seasonal vaccination with RTS,S\/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial","volume":"24","author":"Dicko","year":"2024","journal-title":"Lancet Infect Diss"},{"key":"10.1016\/j.jiph.2026.103356_bib17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2026.103356_bib20","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young african children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib21","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib22","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Tinto","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1473-3099(11)70100-1","article-title":"Safety and efficacy of the RTS,S\/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial","volume":"11","author":"Asante","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib25","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41598-017-07533-w","article-title":"RTS,S\/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103356_bib26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","article-title":"Four-year efficacy of RTS,S\/AS01E and its interaction with malaria exposure","volume":"368","author":"Olotu","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","article-title":"Long-term incidence of severe malaria following RTS,S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial","volume":"19","author":"Tinto","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000164","article-title":"Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area","volume":"2","author":"Bejon","year":"2008","journal-title":"PLOS Negl Trop Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib29","series-title":"Efficacy of GSK biologicals\u2019 candidate malaria vaccine (257049) against malaria disease caused by P. falciparum infection in infants and children in Africa","author":"GlaxoSmithKline","year":"2019"},{"key":"10.1016\/j.jiph.2026.103356_bib30","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(07)61542-6","article-title":"Safety of the RTS,S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I\/IIb trial","volume":"370","author":"Aponte","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899223","article-title":"GMZ2 vaccine-induced antibody responses, naturally acquired immunity and the incidence of malaria in burkinabe children","volume":"13","author":"Dassah","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiph.2026.103356_bib32","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.vaccine.2021.06.024","article-title":"Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine","volume":"39","author":"Dassah","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib33","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib34","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000707","article-title":"Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"2","author":"Bejon","year":"2007","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.jiph.2026.103356_bib37","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.vaccine.2016.04.019","article-title":"Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1\/AS02A vaccine candidate","volume":"34","author":"Graves","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib38","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/600119","article-title":"Long-term safety and efficacy of the RTS,S\/AS02A malaria vaccine in Mozambican children","volume":"200","author":"Sacarlal","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib40","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(22)00273-0","article-title":"Efficacy of RTS,S\/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5\u201317 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial","volume":"22","author":"Samuels","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib41","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2026.103356_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005165","article-title":"Insights into long-lasting protection induced by RTS,S\/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children","volume":"4","author":"Guinovart","year":"2009","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib44","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","article-title":"Safety and Immunogenicity of RTS,S\/AS02D Malaria Vaccine in Infants","volume":"359","author":"Abdulla","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib45","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2020.03.014","article-title":"Immunogenicity and safety of the RTS,S\/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial","volume":"38","author":"Asante","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-11","article-title":"Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S\/AS02D malaria vaccine in infants living in a malaria-endemic region","volume":"12","author":"Abdulla","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.jiph.2026.103356_bib47","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.vaccine.2011.03.041","article-title":"Four year immunogenicity of the RTS, S\/AS02A malaria vaccine in Mozambican children during a phase IIb trial","volume":"29","author":"Aide","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208328","article-title":"First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children","volume":"13","author":"Tiono","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib49","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","article-title":"Duration of protection with RTS,S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial","volume":"366","author":"Alonso","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2007.11.003","article-title":"Safety of the RTS,S\/AS02A malaria vaccine in Mozambican children during a Phase IIb trial","volume":"26","author":"Sacarla","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib51","article-title":"Safety, immunogenicity and duration of protection of the RTS,S\/ASO2D malaria vaccine: One year follow-up of a randomized controlled phase I\/IIb trial","volume":"5","author":"A\u00edde","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jiph.2026.103356_bib52","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","article-title":"Safety profile of the RTS,S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa","volume":"15","author":"Mendoza","year":"2019","journal-title":"Human Vaccin Immunother"},{"key":"10.1016\/j.jiph.2026.103356_bib53","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1473-3099(16)30161-X","article-title":"Safety and immunogenicity of RTS,S\/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial","volume":"16","author":"Otieno","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib54","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1016\/j.vaccine.2014.07.067","article-title":"Immunogenicity and safety of the candidate RTS,S\/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial","volume":"32","author":"Umeh","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jiph.2026.103356_bib55","unstructured":"Greenwood B. A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S\/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined. clinicaltrials.gov, 2022 https:\/\/clinicaltrials.gov\/study\/NCT03143218 (accessed Dec 15, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007302","article-title":"Randomized controlled trial of RTS,S\/AS02D and RTS,S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children","volume":"4","author":"Owusu-Agyei","year":"2009","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib57","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa0807381","article-title":"Efficacy of RTS,S\/AS01E vaccine against malaria in children 5\u201317 months of age","volume":"359","author":"Bejon","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103356_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/0543a689-83a6-4528-92a1-a0f978b47fcb","article-title":"Safety of the malaria vaccine candidate, RTS,S\/AS01E in 5\u201317 month old Kenyan and Tanzanian children","volume":"5","author":"Lusingu","year":"2010","journal-title":"PLOS One"},{"key":"10.1016\/j.jiph.2026.103356_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-8-220","article-title":"Epidemiology of malaria in the forest-savanna transitional zone of Ghana","volume":"8","author":"Owusu-Agyei","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.jiph.2026.103356_bib60","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/INF.0000000000001937","article-title":"Safety and immunogenicity of seven dosing regimens of the candidate RTS,S\/AS01E malaria vaccine integrated within an expanded program on immunization regimen: a phase ii, single-center, open, controlled trial in infants in Malawi","volume":"37","author":"Witte","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiph.2026.103356_bib61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12936-017-1945-2","article-title":"A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania","volume":"16","author":"Simmons","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.jiph.2026.103356_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-025-01078-0","article-title":"The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S\/AS01E","volume":"10","author":"Ali","year":"2025","journal-title":"npj Vaccin"},{"key":"10.1016\/j.jiph.2026.103356_bib63","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-021-00372-x","article-title":"Subclass and avidity of circumsporozoite protein specific antibodies associated with protection status against malaria infection","volume":"6","author":"Seaton","year":"2021","journal-title":"npj Vaccin"},{"key":"10.1016\/j.jiph.2026.103356_bib64","unstructured":"R21 Malaria | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). https:\/\/extranet.who.int\/prequal\/vaccines\/p\/r21-malaria (accessed Dec 12, 2025)."},{"issue":"10437","key":"10.1016\/j.jiph.2026.103356_bib65","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","article-title":"Feasibility, safety, and impact of the RTS, S\/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi","volume":"403","author":"Asante","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103356_bib66","unstructured":"Meeting of the Strategic Advisory Group of Experts on Immunization, September 2025: conclusions and recommendations. World Health organization Weekly epidemiological record Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 2025; No 49, 2025, 100, 605\u2013626. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/37c33e7e-d8c2-488f-b39a-b69e482d7d75\/content (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib67","unstructured":"Patrick E. Duffy, M.D.. National Institute of Allergy and Infectious Diseases (NIAID). Safety, Immunogenicity and Efficacy of Pfs230D1M-EPA\/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali. clinicaltrials.gov, 2024 https:\/\/clinicaltrials.gov\/study\/NCT03917654 (accessed Dec 12, 2025)."},{"key":"10.1016\/j.jiph.2026.103356_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40471-021-00271-8","article-title":"Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S\/AS01e Malaria Vaccine Efficacy","volume":"8","author":"Bell","year":"2021","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.jiph.2026.103356_bib69","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4269\/ajtmh.2012.12-0308","article-title":"Alterations in plasmodium falciparum genetic structure two years after increased malaria control efforts in Western Kenya","volume":"88","author":"Vardo-Zalik","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jiph.2026.103356_bib71","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jiac322","article-title":"Malaria transmission intensity likely modifies RTS, S\/AS01 efficacy due to a rebound effect in Ghana, Malawi, and Gabon","author":"Bell","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2026.103356_bib72","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S1473-3099(22)00273-0","article-title":"Efficacy of RTS,S\/AS01(E) malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial","volume":"22","author":"Samuels","year":"2022","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:25:24Z","timestamp":1791059124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126002285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1876034126002285"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103356","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy, immunogenicity and safety of RTS,S\/AS01, R21\/Matrix-M and candidate malaria vaccines in children: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103356"}}